A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

New England Journal of Medicine

Volumn 334, Issue 17, 1996, Pages 1084-1089

  Schömig, Albert ^a   Neumann, Franz Josef ^a   Kastrati, Adnan ^a   Schühlen, Helmut ^a   Blasini, Rudolf ^a   Hadamitzky, Martin ^a   Walter, Hanna ^a   Zitzmann Roth, Eva Maria ^a   Richardt, Gert ^a   Alt, Eckhard ^a   Schmitt, Claus ^a   Ulm, Kurt ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HEPARIN; PHENPROCOUMON; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PHENPROCOUMON; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 9244251971     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199604253341702     Document Type: Article

References (23)

1. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6
2. George BS, Voorhees WD III, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 1993;22:135-43.
3. Schomig A, Kastrati A, Mudra H, et al Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation 1994;90:2716-24.
4. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease N Engl J Med 1994;331:489-95.
5. Fischman DL, Leon MB, Baim DS, et al A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
6. Topol EJ Caveats about elective coronary stenting N Engl J Med 1994; 331:539-41.
7. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent. initial results of a multicenter study Circulation 1991;83 148-61
8. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88
9. Serruys PW, Emanuelsson H, van der Giessen W, et al Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the Benestent-II Pilot Study. Circulation 1996,93:412-22
10. Neumann FJ, Gawaz M, Ott I, May A, Mössmer G. Schömig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996,27 15-21.
11. Schaub F, Theiss W, Heinz M, Zagel M, Schomig A. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. Circulation 1994;90:1861-5
12. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley, 1981
13. Breslow NE, Day NE Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980 (IARC scientific publications no. 32.)
14. Ellis SG, Vandormael MG, Cowley MJ, et al Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease implications for patient selection. Circulation 1990; 82:1193-202.
15. Schuhlen H, Blasim R, Mudra H, et al. Stenting for progressive dissection during PTCA clinical, angiographic and intravascular ultrasound criteria to define a low-risk group not requiring subsequent anticoagulation. J Am Coll Cardiol 1995;Special Issue:123A-124A. abstract.
16. Freedman JE, Adelman B. Pharmacology of heparin and oral anticoagulants. In: Loscalzo J, Schafer AI, eds Thrombosis and hemorrhage Boston: Blackwell Scientific, 1994 1155-71.
17. Harker LA, Bruno JB. Ticlopidine's mechanism of action on human platelets. In: Hass WK, Easton JD, eds Ticlopidine, platelets and vascular disease. New York: Springer-Verlag, 1993:41-59
18. Coller BS. Platelets and thrombolytic therapy N Engl J Med 1990,322:33-42.
19. Xiao Z, Théroux P, Plachetka JR. Platelet activation and aggregation by therapeutic doses of heparin. J Am Coll Cardiol 1995;Special Issue:117A. abstract.
20. Warkentin TE, Levine MN, Hirsh J, et al Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332 1330-5.
21. Gawaz M, Neumann FJ, Ott I, May A, Schömig A. Platelet activation and coronary stent implantation: effect of antithrombotic therapy Circulation (in press)
22. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients N Engl J Med 1989,321 501-7.
23. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1 1215-20